MAA Approval Support

From pre-submission planning to post-submission query resolution, we provide end-to-end MAA support services to optimize your path to market authorization in the EU.

MAA Approval Support - Overview

The European Medicines Agency (EMA) or other EU Health Authorities (HAs) might need clarification or additional information to technically review the content submitted to them through various procedures, which would be requested to MAH as day 120/150/180/210 queries. The Marketing Authorization Holders (MAHs) must address these queries with scientific inputs and justifications to avoid delays in the review cycle and expedite the Marketing Authorization Application (MAA) approval. While responding to these queries, the MAHs can consider MAA approval support for a comprehensive content review.

To ensure timely MAA submission, the applicants should notify the EMA at least seven (07) months before the planned submission date, providing an estimated submission date to the Agency. Freyr has extensive experience facilitating MAA approvals for various formulations across EU countries.

Some of the services provided by Freyr include MAA approval support, MAA Regulatory submission strategies, and the Generic Drug Approval Process in Europe.

MAA Approval Support - Expertise

  • A thorough review of the deficiencies received from the EMA/other EU HAs against the registered content.
  • Preparation of an action plan with responsibilities to meet the response submission timelines.
  • Preparation of response strategy and guidance to the applicant on activities to be performed.
  • Assessment of additional data and/or inputs and identifying the gaps.
  • Preparation of response package with scientific justifications and supporting documents.
  • Correspondence with the EMA/other EU HAs for extension requests and negotiation on the strategy.
MAA Approval Support

Celebrating Customers Success

 

Medicinal Products

Regulatory Affairs

India

Thank you for the timely support over the weekend, which allowed us to resubmit quickly after being notified. This continuously demonstrates Freyr's commitment towards our company’s milestones.

Director - Global Regulatory Affairs – Operations

India-based, Global Top Generic Pharma Company

 

Medicinal Products

Publishing

UK

I am sure you have heard by now that we have received our first-ever approval from the FDA for our Brands division. This is a major milestone for us as well as for my team here in Reg Ops. I would be remiss if I didn’t point out that we would not have been able to do this without the help of your dedicated team. From the original filing, then the following year of responses, all helped get us to final approval.

Thank you Freyr team for a job well done!

Sr. Director, Head of Regulatory Operations

Ireland-based, Global Specialty Pharmaceutical Company

 

Medicinal Products

Regulatory Affairs

USA

Please relate to the team the excellent job they have done on the IND reactivation. Specifically, the high-quality module 3, written by Freyr. It was very comprehensive, very few revisions were required, and we had no questions from Health Canada or FDA. No CMC questions: that was a first for me. So very responsive to my many requests, which I am sure can be frustrating but always helpful while producing excellent work.

Thank you for always being available and responding quickly and comprehensively to all my requests.

What a great team you have, Freyr.

Lynne McGrath

Regulatory Consultant

 

Medicinal Products

Regulatory Affairs

USA

Congratulations!!! ​

Thanks for your great support for a successful ANDA filing, especially to the publishing team. Heartfully appreciate their last hours of hard work.

Assistant Manager​

US-based, Leading, Complex Generic Pharmaceutical Products Company​

 

Medicinal Products

Regulatory Affairs

USA

Thank you all for the great support!​

CEO

US-based, Leading Innovative Pharmaceuticals Company​

 

Medicinal Products

Regulatory Affairs

USA

The ANDA receipt has been received! Thank you very much for your hard work, patience, and support for our work over the last couple of months. We are delighted that we were able to meet the timeline and hit an important corporate goal of our young company. ​

Thank you again, and we look forward to working with your team on the next project!

Senior Director of Business and Product Development​

US-based, Leading Innovator Pharmaceuticals Company​